# Study of the CD40 Agonistic Monoclonal Antibody APX005M

> **NCT02482168** · PHASE1 · COMPLETED · sponsor: **Apexigen America, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Cancer
- NSCLC
- Melanoma
- Urothelial Carcinoma
- MSI-H
- Head and Neck Cancer

## Interventions

- **DRUG:** APX005M

## Key facts

- **NCT ID:** NCT02482168
- **Lead sponsor:** Apexigen America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-06-13
- **Final completion:** 2018-06-19
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482168, "Study of the CD40 Agonistic Monoclonal Antibody APX005M". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02482168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*